MovDisordV3, Main, Exploration, bibRecord, 005D26

Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

Identifieur interne : 005D26 ( Main/Exploration ); précédent : 005D25; suivant : 005D27

Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

Auteurs : A. J. Hughes [Royaume-Uni] ; Susan Bishop [Royaume-Uni] ; Birgit Kleedorfer [Royaume-Uni] ; Nora Turjanski [Royaume-Uni] ; W. Fernandez [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 1993.

RBID : ISTEX:D5F97C1F370CF8413688F548C3096B925B82BFB4

English descriptors

KwdEn :
- Adult, Aged, Apomorphine, Apomorphine (administration & dosage), Apomorphine (adverse effects), Female, Follow-Up Studies, Humans, Infusion Pumps, Injections, Subcutaneous, Levodopa (administration & dosage), Levodopa (adverse effects), Long-Term Care, Male, Middle Aged, Motor fluctuations, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson's disease.
MESH :
- chemical , administration & dosage : Apomorphine, Levodopa.
- chemical , adverse effects : Apomorphine, Levodopa.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Adult, Aged, Female, Follow-Up Studies, Humans, Infusion Pumps, Injections, Subcutaneous, Long-Term Care, Male, Middle Aged.

Abstract

Subcutaneous apomorphine, administered by continuous waking‐day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on‐off flutuations for 1–5 years. A mean reduction in daily off period time of ∼50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long‐term follow‐up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on‐phase dyskinesias and postural instability marred the long‐term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late‐stage Parkinson's disease and should certainly be considered before experimental implantation procedures.

Url:

https://api.istex.fr/document/D5F97C1F370CF8413688F548C3096B925B82BFB4/fulltext/pdf

DOI: 10.1002/mds.870080208

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years</title>
<author><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A. J." last="Hughes">A. J. Hughes</name>
</author>
<author><name sortKey="Bishop, Susan" sort="Bishop, Susan" uniqKey="Bishop S" first="Susan" last="Bishop">Susan Bishop</name>
</author>
<author><name sortKey="Kleedorfer, Birgit" sort="Kleedorfer, Birgit" uniqKey="Kleedorfer B" first="Birgit" last="Kleedorfer">Birgit Kleedorfer</name>
</author>
<author><name sortKey="Turjanski, Nora" sort="Turjanski, Nora" uniqKey="Turjanski N" first="Nora" last="Turjanski">Nora Turjanski</name>
</author>
<author><name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W." last="Fernandez">W. Fernandez</name>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G. M." last="Stern">G. M. Stern</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D5F97C1F370CF8413688F548C3096B925B82BFB4</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080208</idno>
<idno type="url">https://api.istex.fr/document/D5F97C1F370CF8413688F548C3096B925B82BFB4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A67</idno>
<idno type="wicri:Area/Istex/Curation">002A67</idno>
<idno type="wicri:Area/Istex/Checkpoint">003F93</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Hughes A:subcutaneous:apomorphine:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8474483</idno>
<idno type="wicri:Area/PubMed/Corpus">004C55</idno>
<idno type="wicri:Area/PubMed/Curation">004C55</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004B98</idno>
<idno type="wicri:Area/Ncbi/Merge">004A11</idno>
<idno type="wicri:Area/Ncbi/Curation">004A11</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A11</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Hughes A:subcutaneous:apomorphine:in</idno>
<idno type="wicri:Area/Main/Merge">008F65</idno>
<idno type="wicri:Area/Main/Curation">005D26</idno>
<idno type="wicri:Area/Main/Exploration">005D26</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years</title>
<author><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A. J." last="Hughes">A. J. Hughes</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bishop, Susan" sort="Bishop, Susan" uniqKey="Bishop S" first="Susan" last="Bishop">Susan Bishop</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kleedorfer, Birgit" sort="Kleedorfer, Birgit" uniqKey="Kleedorfer B" first="Birgit" last="Kleedorfer">Birgit Kleedorfer</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Turjanski, Nora" sort="Turjanski, Nora" uniqKey="Turjanski N" first="Nora" last="Turjanski">Nora Turjanski</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W." last="Fernandez">W. Fernandez</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G. M." last="Stern">G. M. Stern</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>Department of Neurology, The Middlesex Hospital, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="165">165</biblScope>
<biblScope unit="page" to="170">170</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D5F97C1F370CF8413688F548C3096B925B82BFB4</idno>
<idno type="DOI">10.1002/mds.870080208</idno>
<idno type="ArticleID">MDS870080208</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Apomorphine</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (adverse effects)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Infusion Pumps</term>
<term>Injections, Subcutaneous</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor fluctuations</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Apomorphine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Infusion Pumps</term>
<term>Injections, Subcutaneous</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Subcutaneous apomorphine, administered by continuous waking‐day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on‐off flutuations for 1–5 years. A mean reduction in daily off period time of ∼50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long‐term follow‐up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on‐phase dyskinesias and postural instability marred the long‐term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late‐stage Parkinson's disease and should certainly be considered before experimental implantation procedures.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hughes, A J" sort="Hughes, A J" uniqKey="Hughes A" first="A. J." last="Hughes">A. J. Hughes</name>
</region>
<name sortKey="Bishop, Susan" sort="Bishop, Susan" uniqKey="Bishop S" first="Susan" last="Bishop">Susan Bishop</name>
<name sortKey="Fernandez, W" sort="Fernandez, W" uniqKey="Fernandez W" first="W." last="Fernandez">W. Fernandez</name>
<name sortKey="Kleedorfer, Birgit" sort="Kleedorfer, Birgit" uniqKey="Kleedorfer B" first="Birgit" last="Kleedorfer">Birgit Kleedorfer</name>
<name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="Stern, G M" sort="Stern, G M" uniqKey="Stern G" first="G. M." last="Stern">G. M. Stern</name>
<name sortKey="Turjanski, Nora" sort="Turjanski, Nora" uniqKey="Turjanski N" first="Nora" last="Turjanski">Nora Turjanski</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D26 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D26 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D5F97C1F370CF8413688F548C3096B925B82BFB4
   |texte=   Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.